Market closedNon-fractional
Allakos/ALLK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Allakos
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Ticker
ALLK
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Carlos, United States
Employees
131
Website
www.allakos.com
Allakos Metrics
BasicAdvanced
$65M
Market cap
-
P/E ratio
-$2.46
EPS
0.84
Beta
-
Dividend rate
Price and volume
Market cap
$65M
Beta
0.84
Financial strength
Current ratio
4.11
Quick ratio
3.877
Long term debt to equity
35.975
Total debt to equity
35.975
Management effectiveness
Return on assets (TTM)
-46.60%
Return on equity (TTM)
-111.56%
Valuation
Price to book
0.62
Price to tangible book (TTM)
0.62
Price to free cash flow (TTM)
-0.537
Growth
Earnings per share change (TTM)
5.64%
3-year earnings per share growth
-11.79%
What the Analysts think about Allakos
Analyst Ratings
Majority rating from 9 analysts.
Allakos Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$71M
13.76%
Profit margin
0.00%
NaN%
Allakos Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.41
-$0.52
-$0.71
-$0.81
-
Expected
-$0.48
-$0.45
-$0.47
-$0.47
-$0.34
Surprise
-14.46%
14.99%
49.82%
73.26%
-
Allakos News
AllArticlesVideos
The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Engage
Accesswire·1 week ago
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
GlobeNewsWire·2 weeks ago
The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Allakos stock?
Allakos (ALLK) has a market cap of $65M as of July 06, 2024.
What is the P/E ratio for Allakos stock?
The price to earnings (P/E) ratio for Allakos (ALLK) stock is 0 as of July 06, 2024.
Does Allakos stock pay dividends?
No, Allakos (ALLK) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Allakos dividend payment date?
Allakos (ALLK) stock does not pay dividends to its shareholders.
What is the beta indicator for Allakos?
Allakos (ALLK) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Allakos stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.